Nasdaq: VRNA | www.veronapharma.com Developing innovative therapies for the treatment of respiratory diseases August 2021 Breath of Innovation™ Forward-looking statements This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this presentation are forward-look ...

Developing innovative therapies for the treatment of respiratory diseases February 2021 Breath of Innovation™ Nasdaq: VRNA | www.veronapharma.com Forward-looking statements This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this presentation are forward-lo ...

Breathtaking science Developing respiratory drugs for better quality of life Jefferies Global Healthcare Conference June 2019 Nasdaq: VRNA AIM: VRP www.veronapharma.com Forward looking statements This presentation contains "forward-looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this pres ...

RPL554 (dual PDE3/4 enzyme inhibitor): Baseline airway reversibility impacts immediate bronchodilation, in contrast to progressive symptom improvement Dave Singh1, Brian T. Maurer,2 Fernando Martinez,3 Thomas Bengtsson4 1. Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 2. Verona Pharma, plc, New York, USA; 3. Weill Cornell Medical College, New York, USA; 4. StatMind AB, Lund, Sweden Introduction Figure 1: Peak FEV1 0–3 h ensifentrine–placebo ...